Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Chairman’s Address to Shareholders 2020 Annual General Meeting

November 18, 2020November 18, 2020 Alterity Therapeutics

Chairman’s Address to Shareholders 2020 AGM

Post navigation

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

AGM 2020 Presentation

Related Posts

Notice of General Meeting 2019

March 13, 2019

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

October 5, 2018

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

May 21, 2020May 21, 2020

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent Posts

Alterity Half Year Results and Investor Webcast Notification
Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials
Quarterly Cash Flow Report
New hope in global fight against antibiotic resistant superbugs
Alterity participates in world’s largest virtual healthcare conference JP Morgan

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065